Edwards Lifesciences Reports Q1 Growth with Revenue Surge to $1.65 Billion

Edwards Lifesciences Corp. (EW) has reported a growth in net income for the first quarter, driven by a strong increase in top-line revenue. The results reflect a steady expansion in the company's market position, with GAAP earnings rising to $380.7 million compared to $363.6 million in the same period last year. Revenue for the quarter grew 16.7% year-over-year, reaching $1.648 billion from $1.412 billion. On a per-share basis, GAAP EPS rose to $0.66 from $0.62. When excluding specific items, the company reported adjusted earnings of $455.2 million, or $0.78 per share. Looking ahead, the company issued optimistic projections for the immediate future. For the next quarter, Edwards expects EPS to fall between $0.70 and $0.76, with revenue projected to range from $1.66 billion to $1.74 billion. The full-year outlook remains robust, with revenue guidance set between $6.5 billion and $6.9 billion and EPS projected between $2.95 and $3.05. These figures suggest continued demand for the company's medical technology, likely supporting a stable to positive outlook for the stock in the short term.